今日药学

2021, v.31(04) 318-320

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

1例纳武利尤单抗致免疫性肝损伤的病例分析
A Case Analysis of Immune Liver Injury Induced by Nivolumab

周守宁;何玉文;谢晓鸿;周承志;
ZHOU Shouning;HE Yuwen;XIE Xiaohong;ZHOU Chengzhi;Department of Pharmacy,The First Affiliated Hospital of Guangzhou Medical University;Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University;

摘要(Abstract):

目的探讨纳武利尤单抗致免疫性肝损伤的临床特点和防治原则。方法回顾1例非小细胞肺癌患者接受肿瘤免疫治疗过程中的病程变化,结合纳武利尤单抗的临床研究、免疫相关不良反应的诊治规范,对本案例进行分析。结果纳武利尤单抗导致了患者出现免疫性肝损伤。在停药予以对症处理后,患者预后良好。结论在抗肿瘤免疫治疗的过程中,需要防范免疫相关不良反应,保证用药安全性和有效性。
OBJECTIVE To explore the clinical characteristics and treatment principles of immune liver injury induced by nivolumab. METHODS Immune liver injury induced by nivolumab was occurred in a case with non-small cell lung cancer, which was analyzed retrospectively combining with the clinical study of nivolumab and the diagnosis and treatment norms of immune-related adverse reactions(irAEs). RESULTS The patientwas occurred immune liver injury induced by Nivolumab.After withdrawal of nivolumaband symptomatic treatment, the patientrecovered. CONCLUSION It is necessary to guard against immune-related adverse reactions during immunotherapy to ensure the safety and effectiveness of drug use.

关键词(KeyWords): 纳武利尤单抗;非小细胞肺癌;免疫性肝损伤
nivolumab;NSCLC;immune liver injury

Abstract:

Keywords:

基金项目(Foundation): 广东省医学科学技术研究基金(A2020413)

作者(Authors): 周守宁;何玉文;谢晓鸿;周承志;
ZHOU Shouning;HE Yuwen;XIE Xiaohong;ZHOU Chengzhi;Department of Pharmacy,The First Affiliated Hospital of Guangzhou Medical University;Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University;

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享